Identify CKD and comorbid hypertension phenotypes and understand the poor prognostic implications for these patients

Cardiorenal disease is associated with an increased risk of morbidity, hospitalisation and mortality, and RAAS inhibitors are standard-of-care for these

Several novel therapies have been approved for the treatment of CKD in recent years and one class of agents, SGLT2 inhibitors, have been positioned